3F to start US heart valve trial:
This article was originally published in Clinica
Executive Summary
Privately held medical device company 3F Therapeutics has gained the green light to start the US arm of a clinical trial to assess its heart valve. The aortic bioprosthesis has already been implanted in the first five patients in the European portion of the trial. "Approximately 260,000 prosthetic heart valves are implanted worldwide every year, a market currently served by much bigger companies including Medtronic, St Jude Medical, Edwards Lifesciences, Sulzer Carbomedics, and ATS Medical," says Walter Cuevas, president and CEO of Orange County, california-based 3F.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.